Resources

Press Release
January 23rd, 2023

CytoReason to License Its IBD Disease Model to Sanofi in Expanded Multiyear, Multimillion Dollar Deal

Media Coverage
November 29th, 2022

Poolbeg Pharma reaches R&D milestone as partner CytoReason completes AI influenza disease model

Poolbeg Pharma reaches R&D milestone as partner CytoReason completes AI influenza disease model
Media Coverage
September 22nd, 2022

CytoReason, Pfizer ink $110M, 5-year extension of AI-powered drug development deal

Blog

The Growth Factor

As we expand our partnership with Pfizer in the company’s most significant agreement to date, we find ourselves thinking about the CytoReason “growth factor”—the key agent to our company’s success
Media Coverage
June 24th, 2022

What do you consider the biggest challenge that the pharma/biopharma industry currently faces?

Blog
June 23rd, 2022

The Next Chapter: Harnessing Big Data in Pharma with Computational Disease Models

Bring your data to life